Research progress of mesenchymal stem cells in delaying renal interstitial fibrosis

doi:10.3877/cma.j.issn.2095-3216.2021.04.008

Abstract

Abstract:

Chronic kidney disease (CKD) has a worldwide prevalence of 8%-16%. Renal interstitial fibrosis is the main route of CKD progression, and eventually inevitably develops into end-stage renal disease (ESRD), causing a huge socioeconomic burden. In recent years, mesenchymal stem cells (MSCs) have shown great potential in repairing injury by their multi-directional differentiation and self-renewal ability. Recent studies have found that MSCs can regulate renal interstitial fibrosis-related signaling pathways through the immune response and paracrine effects, inhibit tubular epithelial-mesenchymal transition (EMT), and thereby delay renal interstitial fibrosis. This article reviewed the mechanism, related researches, and existing challenges of MSCs in delaying renal interstitial fibrosis.

Key words: Mesenchymal stem cells, Renal interstitial fibrosis

Xiaolei Shi, Lihua Liu, Xuehong Lu. Research progress of mesenchymal stem cells in delaying renal interstitial fibrosis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(04): 227-231.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.04.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I04/227

Figures/Tables 1

References 40

[1]	Ishiuchi N, Nakashima A, Doi S, et al. Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats [J]. Stem Cell Res Ther, 2020, 11(1): 130.
[2]	Humphreys BD. Mechanisms of renal fibrosis [J]. Annu Rev Physiol, 2018, 80: 309-326.
[3]	Zhuang Q, Ma R, Yin Y, et al. Mesenchymal stem cells in renal fibrosis: the flame of cytotherapy [J]. Stem Cells Int, 2019, 2019: 8387350.
[4]	Lin S, Yu L, Ni Y, et al. Fibroblast growth factor 21 attenuates diabetes-induced renal fibrosis by negatively regulating TGF-β-p53-Smad2/3-mediated epithelial-to-mesenchymal transition via activation of AKT [J]. Diabetes Metab J, 2020, 44(1): 158-172.
[5]	Xie M, Wan J, Zhang F, et al. Influence of hepatocyte growth factor-transfected bone marrow-derived mesenchymal stem cells towards renal fibrosis in rats [J]. Indian J Med Res, 2019, 149(4): 508-516.
[6]	Lee M, Kim SH, Jhee JH, et al. Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis [J]. Stem Cell Res Ther, 2020, 11(1): 422.
[7]	Yu P, Wang Z, Liu Y, et al. Marrow mesenchymal stem cells effectively reduce histologic changes in a rat model of chronic renal allograft rejection [J]. Transplant Proc, 2017, 49(9): 2194-2203.
[8]	Brennan Má, Layrolle P, Mooney DJ. Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration [J]. Adv Funct Mater, 2020, 30(37): 1909125.
[9]	Yun CW, Lee SH. Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute/chronic kidney disease [J]. Int J Mol Sci, 2019, 20(7): 1619.
[10]	Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: cell therapy and regeneration potential [J]. J Tissue Eng Regen Med, 2019, 13(9): 1738-1755.
[11]	Kim SR, Zou X, Tang H, et al. Increased cellular senescence in the murine and human stenotic kidney: effect of mesenchymal stem cells [J]. J Cell Physiol, 2021, 236(2): 1332-1344.
[12]	Gewin LS. Renal fibrosis: primacy of the proximal tubule [J]. Matrix Biol, 2018, 68-69: 248-262.
[13]	Makhlough A, Shekarchian S, Moghadasali R, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: a safety study with 18 months of follow-up [J]. Cytotherapy, 2018, 20(5): 660-669.
[14]	Li M, Jiang T, Zhang W, et al. Human umbilical cord MSC-derived hepatocyte growth factor enhances autophagy in AOPP-treated HK-2 cells [J]. Exp Ther Med, 2020, 20(3): 2765-2773.
[15]	Yoshida K, Nakashima A, Doi S, et al. Serum-free medium enhances the immunosuppressive and antifibrotic abilities of mesenchymal stem cells utilized in experimental renal fibrosis [J]. Stem Cells Transl Med, 2018, 7(12): 893-905.
[16]	Kim HS, Lee JS, Lee HK, et al. Mesenchymal stem cells ameliorate renal inflammation in adriamycin-induced nephropathy [J]. Immune Netw, 2019, 19(5): e36.
[17]	Song Y, Lv S, Wang F, et al. Overexpression of BMP-7 reverses TGF-beta 1-induced epithelial-mesenchymal transition by attenuating the Wnt3/beta-catenin and TGF-beta 1/Smad2/3 signaling pathways in HK-2 cells [J]. Mol Med Rep, 2020, 21(2): 833-841.
[18]	Chen L, Yang T, Lu DW, et al. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment [J]. Biomed Pharmacother, 2018, 101: 670-681.
[19]	Marcheque J, Bussolati B, Csete M, et al. Concise reviews: stem cells and kidney regeneration: an update [J]. Stem Cells Transl Med, 2018, 8(1): 82-92.
[20]	Li C, Xiao Q, Gu C, et al. Hepatocyte growth factor inhibits renal angiotensin II expression in 5/6 nephrectomized rats [J]. Ann Clin Lab Sci, 2020, 50(5): 578-583.
[21]	Lv W, Booz GW, Wang Y, et al. Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets [J]. Eur J Pharmacol, 2018, 820: 65-76.
[22]	Chang JW, Tsai HL, Chen CW, et al. Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial-to-mesenchymal transition and immune modulation [J]. J Cell Mol Med, 2012, 16(12): 2935-2949.
[23]	Katsuno T, Ozaki T, Saka Y, et al. Low serum cultured adipose tissue-derived stromal cells ameliorate acute kidney injury in rats [J]. Cell Transplant, 2013, 22(2): 287-297.
[24]	Wiklander OPB, Brennan Má, Lotvall J, et al. Advances in therapeutic applications of extracellular vesicles [J]. Sci Transl Med, 2019, 11(492): eaav8521.
[25]	Fan M, Zhang J, Xin H, et al. Current perspectives on role of MSC in renal pathophysiology [J]. Front Physiol, 2018, 9: 1323.
[26]	Grange C, Tritta S, Tapparo M, et al. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy [J]. Sci Rep, 2019, 9(1): 4468.
[27]	Shi Z, Wang Q, Zhang Y, et al. Extracellular vesicles produced by bone marrow mesenchymal stem cells attenuate renal fibrosis, in part by inhibiting the RhoA/ROCK pathway, in a UUO rat model [J]. Stem Cell Res Ther, 2020, 11(1): 253.
[28]	Wang Y, Guo YF, Fu GP, et al. Protective effect of miRNA-containing extracellular vesicles derived from mesenchymal stromal cells of old rats on renal function in chronic kidney disease [J]. Stem Cell Res Ther, 2020, 11(1): 274.
[29]	Zhao M, Liu S, Wang C, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA [J]. ACS Nano, 2021, 15(1): 1519-1538.
[30]	Liu Y, Cui J, Wang H, et al. Enhanced therapeutic effects of MSC-derived extracellular vesicles with an injectable collagen matrix for experimental acute kidney injury treatment [J]. Stem Cell Res Ther, 2020, 11(1): 161.
[31]	da Silva AF, Silva K, Reis LA, et al. Bone marrow-derived mesenchymal stem cells and their conditioned medium attenuate fibrosis in an irreversible model of unilateral ureteral obstruction [J]. Cell Transplant, 2015, 24(12): 2657-2666.
[32]	Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis [J]. Stem Cell Res Ther, 2020, 11(1): 336.
[33]	Baulier E, Favreau F, Le Corf A, et al. Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation [J]. Stem Cells Transl Med, 2014, 3(7): 809-820.
[34]	Maruyama T, Fukuda N, Matsumoto T, et al. Systematic implantation of dedifferentiated fat cells ameliorated monoclonal antibody 1-22-3-induced glomerulonephritis by immunosuppression with increases in TNF-stimulated gene 6 [J]. Stem Cell Res Ther, 2015, 6(1): 80.
[35]	Franquesa M, Herrero E, Torras J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model [J]. Stem Cells Dev, 2012, 21(17): 3125-3135.
[36]	Moghadasali R, Hajinasrollah M, Argani H, et al. Autologous transplantation of mesenchymal stromal cells tends to prevent progress of interstitial fibrosis in a rhesus Macaca mulatta monkey model of chronic kidney disease [J]. Cytotherapy, 2015, 17(11): 1495-1505.
[37]	Lohmann S, Eijken M, Møldrup U, et al. Ex vivo administration of mesenchymal stromal cells in kidney grafts against ischemia reperfusion injury-effective delivery without kidney function improvement posttransplant [J]. Transplantation, 2020: 105(3): 517-528.
[38]	Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study [J]. Stem Cells Transl Med, 2013, 2(2): 107-111.
[39]	Kim JS, Lee JH, Kwon O, et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy [J]. Kidney Res Clin Pract, 2017, 36(2): 200-204.
[40]	Ullah M, Liu DD, Rai S, et al. Pulsed focused ultrasound enhances the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles in acute kidney injury [J]. Stem Cell Res Ther, 2020, 11(1): 398.

纤维化模型	MSCs来源	注射方式	分子靶标	作用	参考文献
STZ-DN	UC-MSCs	尾静脉	TGF-β	炎性细胞浸润↓	[16]
			TNF-α	肾间质纤维化↓
UUO	BM-MSCs	肾动脉	a-SMA	ECM沉积↓	[10]
			HGF	肾间质纤维化↓
UUO	BM-MSCs	腔静脉	TNF-α	调节胶原沉积	[28]
			a-SMA	肾纤维化进展↓
I/R	AF-MSCs	肾动脉	TGF-β	炎性细胞浸润↓	[29]
			VEGF	肾纤维化进展↓
I/R	BM-MSCs	肾动脉	TGF-β	纤维化相关mRNA↑	[33]
			VEGF	肾纤维化无改善
CAN	BM-MSCs	尾静脉	IL-6	炎性细胞浸润↓	[31]
			IL23a	肾间质纤维化↓
			IL7R
顺铂诱导恒河猴CKD模型	BM-MSCs	肾动脉		肾纤维化进展↓	[32]
mAb1-22-3诱导慢性肾炎	DFAT	尾静脉	IL-6	炎性细胞浸润↓	[30]
			IL-10	肾间质纤维化↓
			IL-12β
			TSG-6

纤维化模型	MSCs来源	注射方式	分子靶标	作用	参考文献
STZ-DN	UC-MSCs	尾静脉	TGF-β	炎性细胞浸润↓	[16]
			TNF-α	肾间质纤维化↓
UUO	BM-MSCs	肾动脉	a-SMA	ECM沉积↓	[10]
			HGF	肾间质纤维化↓
UUO	BM-MSCs	腔静脉	TNF-α	调节胶原沉积	[28]
			a-SMA	肾纤维化进展↓
I/R	AF-MSCs	肾动脉	TGF-β	炎性细胞浸润↓	[29]
			VEGF	肾纤维化进展↓
I/R	BM-MSCs	肾动脉	TGF-β	纤维化相关mRNA↑	[33]
			VEGF	肾纤维化无改善
CAN	BM-MSCs	尾静脉	IL-6	炎性细胞浸润↓	[31]
			IL23a	肾间质纤维化↓
			IL7R
顺铂诱导恒河猴CKD模型	BM-MSCs	肾动脉		肾纤维化进展↓	[32]
mAb1-22-3诱导慢性肾炎	DFAT	尾静脉	IL-6	炎性细胞浸润↓	[30]
			IL-10	肾间质纤维化↓
			IL-12β
			TSG-6

Please choose a citation manager

Content to export